Depression is a common mental disorder, and according to the World Health Organization (WHO), more than 350 million people in the world are suffering from depression, and the number is growing rapidly. Depression is associated with a lack of concentration, depressed mood, slowed thinking, sleep disorders, changes in appetite and weight, as well as pessimistic and even suicidal thoughts. There are more than 800,000 people dying each year due to depression.

Medication is the main means of depression treatment. In recent decades, a series of antidepressants have been developed. However, existing antidepressants have certain limitations, such as lagging clinical effects or low response, as well as a series of potential side effects. Since the development of antidepressants is relatively slow compared to the many incidences of depression, it has been included by WHO as one of the most urgent drugs to be developed in the 21st century.

The TargetMol antidepressant compound library collects 1163 compounds related to depression, including compounds that have been reported to have therapeutic effects in depression, as well as compounds that target depression-related targets.